Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans
and its incidence continues to rise. Although CSCC usually display a benign clinical …

The epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB
family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival …

Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from
therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the …

Background We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and
leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought …

Background Treatment with cetuximab, a monoclonal antibody directed against the
epidermal growth factor receptor, improves overall and progression-free survival and …

Abstract PI3K/AKT signaling leads to reduced apoptosis, stimulates cell growth and
increases proliferation. Under normal conditions, PI3K/AKT activation is tightly controlled …

Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can
downsize tumours for curative resection. We assessed the effectiveness of cetuximab …

Functional activation of growth factors and receptors of the epidermal growth factor receptor
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …

Context Patients with metastatic colorectal cancer who have KRAS codon 12–or KRAS
codon 13–mutated tumors are presently excluded from treatment with the anti–epidermal …